Malaria: Difference between revisions

Line 171:

[https://www.ncbi.nlm.nih.gov/books/NBK1706/ by W. Ripley Ballou and Conor P. Cahill NIH]

GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily on the company’s global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and commercialization.

=====Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine=====

[https://www.nature.com/articles/srep46621 by Katharine A. Collins 19/4/17 scientific reports]

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based particle vaccine, RTS,S, which targets the pre-erythrocytic stage of Plasmodium falciparum infection. It induces modest levels of protective efficacy, thought to be mediated primarily by CSP-specific antibodies. We aimed to enhance vaccine efficacy by generating a more immunogenic CSP-based particle vaccine and therefore developed a next-generation RTS,S-like vaccine, called R21.

Malaria: Difference between revisions

Lilly (talk | contribs)

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 171: / Line 171: @@
 [https://www.ncbi.nlm.nih.gov/books/NBK1706/ by W. Ripley Ballou and Conor P. Cahill NIH]
   GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily on the company’s global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and commercialization.
+=====Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine=====
+[https://www.nature.com/articles/srep46621 by Katharine A. Collins 19/4/17 scientific reports]
+ The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based particle vaccine, RTS,S, which targets the pre-erythrocytic stage of Plasmodium falciparum infection. It induces modest levels of protective efficacy, thought to be mediated primarily by CSP-specific antibodies. We aimed to enhance vaccine efficacy by generating a more immunogenic CSP-based particle vaccine and therefore developed a next-generation RTS,S-like vaccine, called R21.